Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

C 08001

Next Previous
Drug Profile

C 08001

Alternative Names: C08001; Carvedilol CR INNOPHARMAX; Inno-C08001

Latest Information Update: 20 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator INNOPHARMAX
  • Class Antihypertensives; Carbazoles; Ethanolamines; Heart failure therapies; Ischaemic heart disorder therapies; Phenyl ethers; Propanolamines; Small molecules
  • Mechanism of Action Alpha 1 adrenergic receptor antagonists; Alpha beta adrenergic receptor antagonists; Beta adrenergic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Heart failure; Hypertension; Myocardial infarction
  • No development reported Cardiovascular disorders

Most Recent Events

  • 20 Dec 2024 Phase-III clinical trials in Heart failure is ongoing in Taiwan (PO) (Immediate release) (Controlled release) (INNOPHARMAX website, December 2024)
  • 20 Dec 2024 Phase-III clinical trials in Hypertension is ongoing in Taiwan (PO) (Immediate release) (Controlled release) (INNOPHARMAX website, December 2024)
  • 20 Dec 2024 Phase-III clinical trials in Myocardial infarction is ongoing in Taiwan (PO) (Immediate release) (Controlled release) (INNOPHARMAX website, December 2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top